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ApoE: PHYSIOLOGIC FUNCTIONS AND RISK 
FACTOR FOR ALZHEIMER’S DISEASE
In 1907, the German psychiatrist, Alois Alzheimer, pub-
lished a case report, “On an unusual illness of the cere-
bral cortex,” in which he described what we now know as 
Alzheimer’s disease (AD) (1). More than a century after 
this landmark discovery, AD is now recognized as the most 
common cause of late-life dementia. AD pathology is char-
acterized by the cerebral accumulation of amyloid plaques 
and neurofibrillary tangles, both of which consist predomi-
nantly of specific insoluble protein aggregates. The major-
ity of AD cases are sporadic and have a relatively late onset, 
predominantly after the age of 65. This form of AD is 
known as late-onset AD (LOAD), in contrast to early-onset 
AD, which has a strong genetic component, is often autoso-
mal dominant, and accounts for less than 1% of AD cases 
(2). While most genetic risk factors for LOAD identified in 
the past two decades have a relatively small impact on AD 
risk, extensive epidemiological, clinical, and pathological 
studies have established the APOE gene on chromosome 19 
as the most important genetic risk factor for developing 
LOAD (3–5). This locus encodes a 299 amino acid glyco-
protein (apoE) that is expressed in several cell types, with 
highest expression levels found in the liver and the brain, 
where it is expressed predominantly by astrocytes (6) and, 
to a lesser extent, microglia (7, 8). The human APOE gene 
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alone. Clinical manifestations of AD include progressive 
decline in memory, executive function, language, and other 
cognitive domains. Research efforts within the last three 
decades have identified APOE as the most significant ge-
netic risk factor for late-onset AD, which accounts for 
>99% of cases. The apoE protein is hypothesized to affect 
AD pathogenesis through a variety of mechanisms, from 
its effects on the blood-brain barrier, the innate immune 
system, and synaptic function to the accumulation of 
amyloid- (A). Here, we discuss the role of apoE on the 
biophysical properties and metabolism of the A peptide, 
the principal component of amyloid plaques and cerebral 
amyloid angiopathy (CAA). CAA is characterized by the de-
position of amyloid proteins (including A) in the lepto-
meningeal medium and small arteries, which is found in 
most AD cases but sometimes occurs as an independent 
entity. Accumulation of these pathologies in the brain is 
one of the pathological hallmarks of AD.  Beyond A, we 
will extend the discussion to the potential role of apoE on 
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ber of diverse neurodegenerative diseases.—Huynh, T-P. V., 
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contains several single nucleotide polymorphisms that re-
sult in changes to the coding region of the apoE protein. 
The three most common variants of apoE are apoE2 (cys112, 
cys158), apoE3 (cys112, arg158), and apoE4 (arg112, 
arg158). Although the three most common isoforms differ 
by only one or two amino acids, they have distinct struc-
ture and function, which may explain the differential 
effects they exert on AD risks. Relative to the prevalent 
3/3 genotype, carriers with one copy of the 4 allele 
have an 3.7-fold increase, while those with two copies 
have a 12-fold increase in risks for developing AD. The 2 
allele appears to be protective [odds ratio (OR) = 0.4] rela-
tive to the 3/3 genotype (9–11).
Like other apolipoproteins, apoE primarily functions to 
maintain the structure of specific lipoprotein particles, as 
well as to direct lipoproteins to specific cell surface recep-
tors. apoE is found in a class of HDL-like lipoprotein in the 
cerebrospinal fluid (CSF) and interstitial fluid (ISF) of the 
brain (12, 13). In the periphery, apoE is associated with 
many different classes of lipoproteins, including VLDLs, in-
termediate density lipoproteins, chylomicron remnants, 
and a subclass of HDL (6). Mice (14) and humans (15) lack-
ing apoE suffer from marked peripheral hypercholesterol-
emia. In the CNS, in vitro experiments have suggested that 
apoE supports synaptogenesis (16) and the maintenance of 
synaptic connections (17), by virtue of the cholesterol spe-
cies it carries. However, there is not strong evidence that it 
has this function in vivo. Furthermore, both in vitro (18, 19) 
and in vivo (20, 21) evidence support a role of apoE in neu-
ronal sprouting after injury. Perhaps unexpectedly, in the 
absence of injury, brain function appears to be grossly nor-
mal in the absence of apoE, as observed in both mice (22, 23) 
and humans (15). This raises the question of whether the 
increased risk of 4 is due to a loss of protective function or 
a gain of toxic function. Though the answer to this question 
is not definitive, numerous studies have suggested that one 
major mechanism by which apoE affects AD pathology is 
through its influence on the accumulation of amyloid 
plaques in the brain and cerebrovasculature.
APOE AND THE AMYLOID- PROTEIN
Amyloid plaques are one of the pathological hallmarks 
of AD and consist mostly of aggregated fibrils of amyloid- 
(A). A peptides are 38–43 amino acids in length, al-
though the most common species found in AD brains by 
far are A1-40 (A40) and A1-42 (A42). A is generated 
by sequential cleavage of the amyloid precursor protein 
(APP) by - and -secretases. The precise location and the 
number of cleavages determine the ultimate length of the 
peptide. Autosomal dominantly inherited missense muta-
tions in APP or components of the human -secretase com-
plex, such as presenilin (PS)1 or PS2 (24), appear to cause 
early-onset AD by increasing A production or by increas-
ing the ratio of A42 relative to A40 (25). In vitro kinetic 
studies indicate that A42 is more prone to aggregation 
and that A peptides ending at amino acid 42 (e.g., A1-42 
or A3-42), specifically, play a critical role in determining 
the rate of amyloid formation (26).
The link between apoE and AD, and apoE and A par-
ticularly, was first suggested in the early 1990s, when apoE 
was found to colocalize with amyloid plaques (27, 28). Sub-
sequently, the 4 allele of apoE was identified as a strong 
genetic risk factor for AD (5, 29, 30). Histopathologic ex-
amination of postmortem brains from AD patients found a 
positive correlation between senile plaque density and dos-
age of the APOE-4 allele (29, 31). While some studies did 
not reproduce the aforementioned findings (32, 33), a 
more recent study that examined a large (n = 296) cohort 
of autopsied AD brains found a significant correlation be-
tween the APOE-4 allele and neuritic plaques (34). The 
development (35) and clinical utilization (36) of Pitts-
burgh compound-B (PiB) as a positron emission topogra-
phy tracer for amyloid deposits revolutionized how AD is 
diagnosed and monitored. A thioflavin T derivative, radio-
isotope-labeled PiB readily crosses the blood-brain barrier 
(BBB) (37) and provides a quantitative in vivo detection of 
amyloid plaques. Early clinical studies utilizing PiB in cogni-
tively normal middle-aged and older people found APOE-4 
gene dosage to be associated with fibrillar A burden (38, 39), 
along with low CSF A42 (39, 40). Consistent with prior 
epidemiological observations, APOE-2 carriers rarely de-
velop fibrillar A that is detected by PiB (39). Altogether, 
data from human studies make a strong case for the apoE 
genotype as a strong susceptibility factor for cerebral amy-
loid plaque accumulation and eventual development of AD.
Aside from clinical investigations, a significant amount 
of basic research effort in the field has focused on under-
standing the effects of apoE on the accumulation of amy-
loid plaques and cerebral amyloid angiopathy (CAA) in 
the brain. Deposition of A into insoluble plaques depends 
on several factors, including the rate of production, clear-
ance from the brain ISF (where amyloid plaques are 
found), and the rate of fibrillization, all of which may be 
influenced by apoE. We discuss the current state of knowl-
edge on each aspect of the process below.
APOE and A production
Among the multitude of factors that have been hypoth-
esized to affect A deposition, studies on apoE’s role in A 
production are probably the most controversial. In vitro 
studies from one group using rat neuroblastoma B103 
cells that express human APP suggested that lipid-poor 
apoE4 enhanced A production compared with lipid-poor 
apoE3, and that this effect was mediated through the LRP 
pathway (41). A very recent study shows that recombinant 
and HEK cell-derived apoE can increase A synthesis in 
human embryonic stem cell-derived neurons in vitro in an 
isoform-dependent fashion (apoE4 > apoE3 > apoE2) 
(Fig. 1, dashed red arrow)(42). The observed phenome-
non was driven by differences in the isoforms’ ability to 
bind and activate surface apoE receptors, which ultimately 
activate cFos-containing AP-1 transcription factors and in-
crease APP transcription. Of note, APP transcription was 
maximally activated when human neurons were cocul-
tured with glial cells (which secrete several glial-derived 
factors), and the isoform-specific effects were abolished 
under such conditions. However, other in vitro and in vivo 
 at W
ashington Univ M









826 Journal of Lipid Research Volume 58, 2017
studies found no apparent apoE isoform effect on APP 
processing and A production (43–45). In agreement with 
the latter findings, in vivo data from APP transgenic (Tg) 
mice found no changes in amyloidogenic processing of 
APP or A synthesis rates according to human apoE iso-
forms (46). These conflicting findings might be explained 
by their different experimental conditions, such as the 
lipidation state of apoE and the experimental model sys-
tem used to generate A. Harmonizing the disparate in 
vitro and in vivo findings on the role of APOE on A pro-
duction will require additional studies. Future work assess-
ing A synthesis in the presence of different apoE isoforms 
in vivo in animal models that have the endogenous APP 
promoter, as well as in humans, will provide insight into 
this important question.
APOE-A interaction
Early studies that focused on the direct interaction be-
tween apoE and A yielded contradictory findings. apoE 
was first proposed to be an A binding partner in 1992 
(28). Various studies showed that synthetic A avidly forms 
a complex with apoE purified from human CSF (5), plasma 
(47), or the conditioned media of apoE-expressing HEK 
cells (48). However, the affinity of different apoE isoforms 
for A appears to be highly dependent on the preparation 
condition of apoE and the species of A involved (soluble 
versus fibrillar), as well as the pH level. Allan Roses’ group 
found apoE4 to bind synthetic A more rapidly than apoE3 
(47, 49), while LaDu et al. (48) found lipidated apoE3 to 
be a much more efficient binding partner of A (20-fold) 
than apoE4. These differences might be explained by the 
lipidation state of the apoE species being used, as several 
other groups confirmed that the efficiency of complex for-
mation between lipidated apoE and A follows the order of 
apoE2 > apoE3 >> apoE4 (50–52). However, one study 
noted that the observed apoE-A complex represents only 
a small proportion of the incubated apoE, despite a large 
molar excess of A (48). In support of this notion, a previ-
ous study from our group provided both in vitro and in vivo 
evidence that more than 95% of the soluble A (sA) de-
tected is not associated with apoE-containing lipoproteins 
(53). sA is defined as any A species that is soluble in 
phosphate-buffered saline, including monomeric and oligo-
meric A. Using various techniques, including density- 
gradient centrifugation, size-exclusion chromatography, 
and fluorescence correlation spectroscopy, the aforemen-
tioned study provided multiple lines of evidence that sA is 
a very poor binding partner of apoE-containing lipopro-
teins (Fig.1, dashed blue arrow). The metastable nature of 
A oligomers had made it difficult to study in the past, but 
it is important for future studies to further dissect out the 
potentially different role of monomeric versus oligomeric 
A in the context of apoE interactions. Indeed, a study us-
ing an ELISA assay specific for A oligomers found the lat-
ter species to be rapidly sequestered away from the ISF and 
CSF in J20 hAPP Tg mice (54). From these results, if oligo-
meric A is present in the ISF, it could be the predominant 
species that interacts with apoE in the ISF prior to binding 
to other cell surface molecules, such as receptors, thus 
leaving monomeric A to be the predominant species to 
be detected in the fluid phase. A recently developed 
method for isolating and characterizing the different oligo-
meric A species may facilitate more rigorous studies on 
the relative contribution of monomeric and oligomeric A 
to the APOE-mediated effects on amyloid pathology pro-
gression (55). This is an important question to address, 
considering the substantial body of literature supporting 
the role of A oligomers in facilitating neurotoxicity (56).
Upon examining functional consequences of the apoE/
A interaction, Tamamizu-Kato et al. (57) found that A 
binding to apoE compromises its lipid-binding function 
in vitro. Thus, it is possible that apoE interacts with A  
directly through the carboxy terminal domain that also 
overlaps with the lipid-binding region. Furthermore, some 
studies suggest that A peptides modulate the binding of 
apoE isoforms differently to apoE receptors (58, 59). These 
in vitro data suggest that A peptides can modulate or in-
terfere with the normal function of apoE.
APOE and A aggregation
The aggregation of A into higher-order species follows 
nucleation-dependent kinetics with a typical three-phase 
sigmoidal curve when assessed in vitro. The initial “lag 
phase” is slow and requires random collision of A mono-
mers (26, 60). Upon formation of a sufficient amount of 
nucleating higher-order species of A (termed “nuclei” or 
“seeds”), perhaps consisting mostly of A oligomers, the 
incorporation of additional monomers (growth phase) oc-
curs at a much faster rate. The rate of fibril growth slows 
down (plateau phase) when it is outcompeted by newly 
formed nuclei or, possibly, depletion of the local pool of 
monomer. Thus, apoE could potentially exert pro-amy-
loidogenic effects by influencing either the formation of 
A seeds or the subsequent elongation of fibrils (Fig. 1).
All three isoforms of apoE have been previously shown 
to promote the fibrillization of A in vitro, and the potency 
follows the order of apoE4 > apoE3 > apoE2 (49, 61, 62). 
On the contrary, other studies suggest that apoE isoforms 
can also inhibit A aggregation, with apoE4 being least 
effective (63–66). These seemingly contradicting find-
ings may be explained by the variable experimental con-
ditions, such as the species and source of A used (67) 
(A40 versus A42, recombinant versus synthetic) and, 
especially, the preparation and the (resulting) lipidation 
state of apoE. Some studies utilized poorly lipidated 
apoE, while the most abundant and biologically active 
species of apoE found in vivo are lipidated. Indeed, in 
vivo studies have shown that alteration of the apoE lipida-
tion state in the brain can exert a profound impact on A 
fibrillization. Nascent apoE peptides in the brain are nor-
mally lipidated by ABCA1. Interestingly, APP Tg mice 
crossed onto an Abca1/ background exhibit a marked 
increase in amyloid deposition, along with a decrease in 
apoE lipidation (68–72). Conversely, overexpression of 
ABCA1 in the brain leads to an increase in apoE lipida-
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To initially assess the effects of human apoE isoforms on 
A in mouse models, Tg mice expressing human apoE iso-
forms under the control of the astrocyte-specific GFAP pro-
moter (in the absence of endogenous murine apoE) were 
crossed with APP Tg mice that develop A plaques. These 
studies showed that, relative to mouse apoE, human apoE 
delayed A deposition, but the order and amount of A 
deposition was apoE4 > apoE3 > apoE2, as is seen in hu-
mans (73, 74). Early in vivo studies on the role of apoE on 
AD-related pathology utilized PDAPP mice, a model of A 
amyloidosis that harbors the human APP transgene with 
the Indiana mutation (V717F) (75, 76). Introduction of 
the human apoE leads to delayed A deposition in com-
parison to PDAPP mice expressing murine apoE or even 
those lacking apoE (74, 77), as was seen in previous studies. 
In 1997, Sullivan et al. (78) generated the first mouse 
strains carrying various isoforms of human apoE through 
targeted replacement. These lines allow for better charac-
terization of the isoform-dependent effects on A aggrega-
tion propensity in that the Apoe gene is regulated by the 
endogenous factors that control its expression. When 
these mice were crossed with different APP Tg mice, there 
was also a strong human apoE isoform-specific effect 
on A deposition in the order of apoE4 > apoE3 > apoE2 
(46, 79). These results are consistent with studies in hu-
mans and confirm the relevance of genetically engineered 
mouse models that mimic at least some aspects of the A 
aggregation component of the disease. Using these hu-
man apoE knock-in mouse models, the allele-dependent 
effects of apoE on A accumulation have been studied 
extensively.
In addition to the isoform effects of APOE, the expres-
sion level of APOE also appears to influence A pathology. 
Deletion of endogenous murine apoE in PDAPP mice, as 
well as in the Tg2576 or APPswe models, leads to signifi-
cantly less A deposition and virtually abolishes fibrillar A 
deposits in the brain parenchyma as well as CAA and CAA-
associated microhemorrhage (80–83). These results sug-
gest that apoE is a critical factor that facilitates A 
aggregation in vivo into a fibrillar form, though the afore-
mentioned studies did not offer insight into the mecha-
nism for such process. To examine the effects of human 
APOE gene dosage, human APOE knock-in mouse lines 
were crossed to APP Tg (APP/PS1-21) mice. Interestingly, 
APP Tg mice expressing only one copy of human apoE 
have significantly less A plaque deposition compared 
with mice expressing two copies of the same apoE isoform 
(either APOE-3 or APOE-4) (84). Very similar findings were 
also found by another group (85), and have potentially im-
portant therapeutic implications because there has been a 
long debate about whether increasing or decreasing apoE 
is beneficial for A pathology. The caveat of these findings 
is that the animals carried the APOE gene and gene dosage 
differences since birth, and there could be developmental 
compensation in the genetic APOE haploinsufficiency 
model that could account for the protective effect against 
A deposition. Whether reducing APOE levels in adult 
mice would similarly affect A burden is unknown. Addi-
tionally, reduction of APOE expression could influence 
both the aggregation and clearance of A, the latter being 
another major effect of apoE on A metabolism that is 
well-described, as discussed in the following section.
Fig. 1. Pathways by which apoE and A interact in the brain. Solid black arrows indicate normal secretion and lipidation of apoE by astro-
cytes. Solid blue arrows indicate the aggregation cascade and potential clearance route for A. Solid red arrows indicate pathways or pro-
cesses that apoE has been shown to influence. Dashed blue arrow indicates a small pool of A-apoE complexes. Dashed red arrow indicates 
apoE’s proposed effect on A production.
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APOE and A clearance
Substantial evidence exists to support the role of apoE 
isoforms on monomeric A clearance. Specifically, apoE 
has been proposed to influence A clearance through sev-
eral mechanisms: enzymatic degradation (86, 87), trans-
port across the BBB (88), ISF-CSF bulk flow, and cellular 
uptake/subsequent degradation (89, 90).
The role of APOE in A transport and clearance. A large 
number of studies support the hypothesis that apoE influ-
ences A transport and clearance from the ISF. The level 
of sA in the ISF can be measured continuously in live 
freely moving animals through utilization of an in vivo mi-
crodialysis technique (91). Clearance of A from the ISF 
was found to be faster in apoE-KO mice (83), suggesting an 
important role for apoE in regulating A levels in the 
brain. apoE isoforms differentially impact the level of ISF 
A and the rate of A clearance in vivo (46). ApoE4- 
expressing mice exhibited higher ISF levels of A and a 
slower rate of A clearance from the ISF than apoE3- 
expressing mice. Conversely, apoE2-expressing mice exhib-
ited a lower level of ISF A and a faster A clearance rate 
relative to apoE3. The isoform-dependent effect of apoE 
was observed in aged mice, but also at young ages, well be-
fore plaque accumulation occurs. These findings suggest 
that the difference in A accumulation between isoforms is 
likely due, in part, to their differential effects on A clear-
ance from the ISF, which can occur through a number of 
mechanisms.
One potential mechanism subject to apoE-dependent 
modulation is the transport of A across the BBB to the 
systemic circulation (Fig. 1). The BBB is a highly selective 
permeability barrier that separates the blood from brain 
ISF. It is formed by continuous capillary endothelial cells 
containing tight junctions, which are surrounded by basal 
lamina, astrocytic perivascular endfeet, and pericytes. 
Through specific transporters, the BBB and pericytes work 
together to control entry of substances from the blood and 
promote clearance from brain of various potentially neuro-
toxic and vasculotoxic macromolecules (92). Similar to 
CAA, AD is associated with microvascular dysfunction and 
a locally defective BBB (93–95), both of which could be 
influenced by A. Intriguingly, carriers of the APOE-4 al-
lele are predisposed to CAA (96–99). In Tg2576 mice, 
apoE4 promotes a shift of A deposition from the brain 
parenchyma to arterioles in the form of CAA, relative to 
apoE3 or murine apoE (100). Consistent with these findings, 
a recent study using 5×-FAD mice (APP Tg mice expressing 
these specific mutations in APP-APP KM670/671NL and 
V717I) harboring both human apoE4 and murine apoE 
found a higher degree of colocalization between murine 
apoE and parenchymal plaques, while plaques in the vascu-
lature contained more apoE4 (101). Mechanistic studies 
linking apoE to A transport from the ISF have identified 
a number of involved transporters, including P-glycopro-
tein (88), LDL receptor-related protein 1 (LRP1) (92), and 
LDL receptor (LDLR) (102).
LRP1 was found in amyloid plaques (103) and can bind 
A directly (104) or indirectly via its ligands, including 
apoE (67, 105) and others (106, 107). Additionally, LRP1 
participates in a lipid transport pathway that involves bind-
ing to heparan sulfate proteoglycans (HSPGs) (108, 109). 
Intriguingly, HSPG was found in senile plaques as well as 
CAA (110–112), and had been shown to directly interact 
with A (113), accelerating its oligomerization and aggre-
gation (Fig. 1) (114–116). A recent study found that abla-
tion of HSPG in postnatal forebrain neurons of APP/PS1 
mice led to a reduction in both A oligomerization and the 
deposition of amyloid plaques (117). These reductions 
were driven by an accelerated rate of A clearance from 
the ISF. Moreover, the authors also found a significantly 
increased level of various HSPG species in postmortem 
brain tissues from AD patients relative to controls. Deletion 
(118) or overexpression (119) of LRP1 causes increases or 
decreases of brain apoE levels, respectively. Whereas A40 
is cleared across the BBB at a much more rapid rate than 
via the ISF flow, binding to apoE-3 reduces the A40 ef-
flux rate from the ISF by 5- to 7-fold (120). Another study 
found that A binding to apoE4 redirects its clearance 
from LRP1 to VLDL receptor, which internalizes A-apoE4 
complexes at the BBB more slowly than LRP1 (121). In 
contrast, A-apoE2 and A-apoE3 complexes are cleared 
through the BBB via both VLDL receptor and LRP1 at 
an accelerated rate compared with that of A-apoE4 
complexes.
In support of LDLR’s role in apoE transport across the 
BBB, deletion of the LDLR gene in the mouse brain leads 
to higher apoE levels in the brain and CSF (122), while 
overexpression of LDLR in the brain decreases brain apoE 
(123). Furthermore, deletion of LDLR caused a decrease 
in A uptake, whereas increasing LDLR levels significantly 
enhanced both the uptake and clearance of A by primary 
astrocytes in culture, even in the absence of apoE (124). 
Taken together, these data suggest that the influence of 
apoE on sA metabolism may not require direct binding of 
apoE with sA in solution, and that A binding to apoE 
may lead to reduced clearance. This raises the possibility 
that APOE isoforms can significantly inhibit the uptake of 
sA by competing for the same pathway, facilitated through 
either LRP1 or LDLR. More rigorous in vivo studies are 
needed to provide direct evidence that the aforementioned 
mechanism is responsible for the increase in A clearance 
in mice with a reduced apoE level.
Independent from its effects on A clearance, there are 
also isoform-specific effects of apoE on the BBB, as expres-
sion of APOE-4 and lack of murine apoE, but not APOE-2 
and APOE-3, was found to lead to BBB breakdown in 
young mice (125). The increase in vascular permeability in 
these mice was linked to a decrease in apoE-dependent 
pericyte-expressed LRP1 activation and a concomitant in-
crease in CypA-MMP9 activity. In support of these findings, 
a human study using postmortem brain samples from con-
trol and AD subjects found accelerated pericyte degenera-
tion in AD APOE-4 carriers compared with AD APOE-3 
carriers and non-AD controls (126). Intriguingly, a signifi-
cant increase in CypA and MMP-9 was also detected in peri-
cytes and endothelial cells of APOE-4 subjects relative to 
APOE-3 subjects. However, in situ brain perfusion using 
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[14C]sucrose as a vascular space marker found no differ-
ences in cerebral vascular volume among mice carrying 
any of the APOE isoforms, despite an observed reduction in 
cerebral vascularization and basement membrane thick-
ness in 12-month-old APOE-4 mice compared with 
APOE-2 and APOE-3 mice (127). Additionally, a relatively 
recently study reported no apparent differences in the 
level of brain IgG and radiotracer uptake in apoE4 or 
apoE/ mice when assessed at 2–3 months of age (128). 
Though the latter results might not be expected, they sug-
gest that the global homeostatic capacity of the BBB might 
be intact in APOE-4 mice, despite highly localized disrup-
tion in BBB integrity.
APOE and cellular metabolism of A. Various cell types in 
the CNS have been shown to possess the ability to internalize 
A, including astrocytes (129), neurons (130), and microglia 
(131–133), albeit with different capabilities. Primary hippo-
campal neurons are more efficient at internalizing A in 
the presence of apoE3 compared with apoE4 (134). Never-
theless, neurons appear to lack the ability to effectively de-
grade A, resulting in formation of high molecular weight 
A species in endosomal vesicles (119, 135). The rest of this 
section will focus on astrocytes and microglia, which probably 
account for a significant amount of cellular A metabolism.
Immunohistological studies on human AD brains using 
antibodies against various A epitopes identified N-terminal-
truncated fragments of A40/42 that are found inside lipo-
fuscin-like granules within astrocytes (89, 90). In agreement 
with human studies, in vitro studies using primary astro-
cytes showed that astrocytes can internalize and degrade 
both soluble (136, 137) and insoluble (138) A. Interest-
ingly, the ability of astrocytes to engulf and degrade A is 
compromised in apoE KO astrocytes, or in WT astrocytes 
upon the addition of either an antibody against A, apoE, 
or an LDLR family antagonist (129). These results suggest 
an essential role of apoE in a receptor-mediated A uptake 
mechanism by astrocytes. However, more recent studies 
provided evidence that such processes can occur in the ab-
sence of apoE (124), and apoE can actually compete with 
A for binding/uptake by LDLR receptors despite mini-
mal interaction with sA (53).
Microglia are the resident macrophages and primary im-
mune effectors in the brain, whose roles in AD are increas-
ingly getting more attention, both in the context of disease 
pathogenesis as well as therapeutic opportunities. Microg-
lia have the ability to clear sA as well as insoluble A in 
vitro, followed by rapid degradation through the late endo-
cytic/lysosomal pathway (133, 139). ApoE has been shown 
to be essential for efficient A degradation via microglia by 
neprilysin or in the extracellular milieu by insulin degrad-
ing enzymes (87). More importantly, this process is depen-
dent on the lipidation status of APOE, suggesting that apoE 
exerts its effects via manipulation of cellular cholesterol 
levels (87, 140). More recently, the newly discovered AD 
risk gene that encodes the triggering receptor expressed 
on myeloid cells 2 (TREM2) (141, 142) protein was found 
to have apoE as one of its ligands (143, 144). Accordingly, 
TREM2-deficient microglia or microglia with an AD risk 
variant (R47H) lose the ability to effectively bind lipopro-
teins (including apoE), which decreases their phagocytic 
capabilities (145). Furthermore, the lipid-sensing compo-
nent of TREM2 allows it to sustain the microglial response 
that is necessary to cluster and potentially play a role in 
more efficient plaque phagocytosis, a phenomenon that is 
attenuated in TREM2-deficient microglia (146), as well as 
R47H mutants (147). Intriguingly, APOE-4-expressing mi-
croglia exhibited more pronounced downregulation of 
TREM2 than those that express APOE-3 in response to 
toll-like receptor (TLR) activation (148). In the future, 
generation of murine models with human TREM2 and mu-
tant variants should allow for more rigorous in vivo studies 
that will fill in the gaps in knowledge about TREM2’s role 
in AD pathogenesis and its potential link with apoE.
APOE AND OTHER AMYLOIDOGENIC PROTEINS
The pro-amyloidogenic nature of APOE has prompted 
investigation of its role in other neurodegenerative dis-
eases, many of which share the common feature of patho-
genic protein aggregation. Specifically, APOE had been 
linked to Parkinson disease (PD) (149, 150), chronic trau-
matic encephalopathy (151), Huntington disease (152, 153), 
frontotemporal dementia (FTD) (154), and certain subsets 
of amyotrophic lateral sclerosis (155–157), though the lat-
ter findings conflicted with some other studies (158–160). 
Here, we discuss the current state of knowledge on the spe-
cific interaction between APOE and the aggregation-prone 
proteins associated with some of these diseases.
APOE and Tau
The strong correlation between APOE genotypes and 
AD, and the presence of immunoreactive apoE in neurons 
containing neurofibrillary tangles (27, 28) led to numer-
ous clinical and epidemiological studies on the potential 
interaction between APOE and Tau, both in the context of 
AD as well as other tauopathies, including FTD. The major-
ity of clinical studies found an over-representation of the 
APOE-4 allele in both AD and FTD (161–164), while histo-
pathologic examinations revealed a significant positive cor-
relation between APOE genotype and stage of neurofibrillary 
pathology (165) according to Braak staging (166). In sup-
port of these findings, the presence of the APOE-4 allele 
significantly correlates with brain atrophy in disease- 
specific brain regions in both AD and FTD (154). However, 
studies have not demonstrated a consistent effect of APOE 
genotype on cognition in tauopathies (154, 167). It should 
be mentioned that a few studies found either no associa-
tion between APOE status and FTD (168), or that the asso-
ciation was only applicable to male cohorts (169). The 
disagreement of these findings might be explained by the 
population being studied and/or the difference in the sta-
tistical power of the studies. More sufficiently powered 
longitudinal studies are necessary to investigate whether 
APOE status has any effect on cognitive status, as well as 
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Early studies by Allen Roses, Warren Strittmatter, and 
colleagues found apoE3, but not apoE4, to interact with 
Tau in an in vitro binding assay (170). This interaction is 
facilitated through the microtubule-binding domain of 
Tau and the LDLR binding domain on apoE3, which is dis-
tinct from its binding site for A. Interestingly, expression 
of full-length human apoE4, specifically in neurons alone, 
is sufficient to induce NFT-like inclusions and hyperphos-
phorylation of Tau in WT mice (171, 172). Along with 
these findings, a C-terminal-truncated fragment of apoE 
(272-299) (172, 173) was found to accumulate in the 
brains of AD patients and mice with neuronal expression of 
APOE (174). The same group also linked the increase in 
pTau to changes in the zinc-induced Erk activation path-
way (175). Considering the availability of mice that develop 
Tau pathology (176) and APOE knock-in (78) mouse mod-
els, future in vivo studies on the APOE/Tau interaction are 
feasible and warrant new insights on the relationship be-
tween one of AD’s signature hallmarks and its biggest risk 
factor.
APOE and -synuclein
-Synuclein (-syn) is a 140 amino acid protein that is 
normally localized to presynaptic terminals. Aggregates of 
-syn form the main constituent of Lewy bodies and Lewy 
neurites (177–179), the pathological hallmarks of a class of 
neurodegenerative diseases termed “synucleinopathies,” 
which includes PD and the related disorders, PD dementia 
and dementia with Lewy bodies [reviewed extensively in 
(180, 181)]. Interestingly, up to 50% of patients with synu-
cleinopathy and dementia also have A plaques, while a 
smaller subset also has concomitant neurofibrillary tangles 
(182–188). Historically, this overlap presented a challenge 
with regard to disease nomenclature. The overlapping fea-
tures between PD and AD have been demonstrated by clini-
cal (189, 190), pathologic (191, 192), and genetic data 
(193, 194). Intriguingly, some of the findings in this area 
suggest a possible connection between apoE and -syn.
Initial epidemiological studies found contradictory re-
sults as to whether APOE genotype influences the risk of 
PD. A meta-analysis of 22 clinical studies found the APOE-2 
allele to be positively associated with risk for developing 
sporadic PD (OR = 1.20), whereas no association was found 
for APOE-3 or APOE-4 (195). On the contrary, an inde-
pendent study by Li et al. (149) genotyped 658 PD-affected 
families for APOE functional polymorphisms and found 
that the APOE-4 allele increased the risk and decreased 
the age at onset for PD, while the APOE-3 allele had the 
opposite effects. Recent efforts to combine data across mul-
tiple genetic association studies have demonstrated that, 
compared with APOE-3, the APOE-2 allele modestly in-
creases risk of PD [OR = 1.11 (95% CI 1.02, 1.21)], while 
APOE-4 has no effect on overall PD risk [OR = 1.00 (95% 
CI 0.91, 1.10)] (196). In addition to the genetic diversity in 
study populations and differences in statistical power, the 
disparity in results may also be attributed to the heteroge-
neity in both clinical and pathologic entities within the PD 
spectrum: that is, many patients with a diagnosis of PD also 
have cognitive impairment and a large, but not necessarily 
overlapping, proportion have A plaque pathology. 
Numerous studies support the association of APOE-4 with 
increased A and, to some extent, Tau pathology in indi-
viduals with PD, as well as other neurodegenerative disor-
ders (197, 198). The effect of APOE-4 on cognitive 
impairment in PD may be mediated, at least in part, 
through A, as illustrated by a prospective cohort study of 
45 patients with PD with at least one yearly follow-up visit in 
which any observed correlation between APOE-4 status 
and cognitive impairment was abolished after adjusting for 
CSF levels of A42. However, this phenomenon does not 
account for the effect of APOE genotype on dementia in 
PD patients who do not have concomitant A plaque pa-
thology (199). Several studies have found that the presence 
of one or more APOE-4 alleles not only increases the A 
plaque load, but also the -syn pathology burden in PD 
cases (183, 200, 201). Interestingly, when a relatively large 
group of PD cases was stratified pathologically and cases 
with concomitant A pathology were excluded (leaving a 
cohort with pure -syn pathology), APOE-4 was still 
strongly associated with dementia and even more strongly 
associated with early development of dementia (202). 
Taken together, these findings suggest that the impact of 
APOE genotype on synucleinopathy and dementia is likely 
multifactorial and that apoE may directly influence -syn 
pathology.
Basic research on the role of APOE on -syn has lagged 
behind clinical and epidemiological studies, but several im-
portant findings have emerged. A study in Tg mice express-
ing mutations in the SNCA gene, which codes for -syn, 
found that aged symptomatic mice had elevated levels 
of endogenous murine A40 and A42, as well as apoE, 
relative to asymptomatic littermates (203). Interestingly, 
deletion of the murine Apoe gene prolonged survival and 
decreased levels of insoluble A40, A42, and -syn, in ad-
dition to decreasing levels of ubiquitinated proteins. These 
data suggest that apoE may directly influence proteostatic 
mechanisms that regulate -syn and A. More recently, an 
in vitro study found that apoE, especially the apoE4 iso-
form, appeared to have a stimulatory effect on -syn aggre-
gation at low concentrations (low nanomoles); however, 
this effect was attenuated at higher concentrations (204). 
One caveat to this study is that the apoE particles used were 
lipid-poor, while most physiologically active apoE species 
found in vivo are lipid-rich. It is also not yet clear how apoE, 
a predominantly secreted molecule found in the extracel-
lular space, interacts with -syn, which localizes to the intra-
cellular space in both monomeric and aggregated forms. 
Further research is clearly needed to elucidate molecular 
mechanisms of this interaction and to explore opportuni-
ties for therapeutic intervention.
FUTURE DIRECTIONS
More than 20 years have passed since the landmark dis-
covery of APOE being linked with AD, and APOE still 
remains the strongest genetic risk factor for LOAD. Inten-
sive research efforts have undoubtedly unveiled several 
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important insights regarding apoE and its role in AD. Nev-
ertheless, no APOE-based (or any) disease-modifying ther-
apy has been approved for AD treatment within this period. 
That means many questions remain unanswered, including 
the most important question: How does APOE gene poly-
morphism confer AD risk? This review focuses mostly on 
the relationship between apoE and A, and to a lesser ex-
tent, Tau and -syn. Taken together, the evidence that 
APOE influences AD risk substantially via effects on A is 
strong. It should be noted that a relatively large body of 
literature also exists to support APOE’s roles in AD patho-
genesis that are A-independent. This area needs much 
further exploration. It is possible that apoE participates in 
an unknown fundamental mechanistic event (such as a 
general signaling cascade) that influences brain homeosta-
sis. If true, the single amino acid change among the differ-
ent isoforms (particularly apoE4) somehow alters the 
behavior/function of apoE in this process that ultimately 
lowers the brain’s ability to tolerate neurotoxic insults 
(such as A or Tau accumulations). This increased vulner-
ability, in turn, could affect AD risk. Similarly, apoE’s poten-
tial role in facilitating the immune response to AD pathology 
needs further investigation. Considering TREM2’s newly 
described role as a lipid-sensing receptor, it is necessary to 
definitively determine whether there is a true meaningful 
connection between APOE and TREM2.
Along with the affordability and availability of big data 
science, there needs to be more studies that look at apoE 
isoforms’ differential effects on specific cell populations in 
the brain in an unbiased fashion. Such studies might iden-
tify novel targets that will allow us to gain a deeper under-
standing as to why AD occurs when it does (old age) and 
where it does (susceptibility regions). Concurrently, re-
searchers should be cautious that considerable species dif-
ferences between rodents and humans exist and might 
challenge our ability to generate findings that are relevant 
and directly translatable to humans from studies in mice 
and rats. Apparent differences in physiological function 
and metabolism, such as lipid metabolism and immune re-
sponse, between humans and rodents might preclude im-
portant discoveries that are relevant to disease mechanism. 
While the current generation of APOE knock-in mice har-
bors the human gene sequence, they retain the regulatory 
elements found in mice. It is critical to address this caveat 
in rodent studies, in lieu of recent studies including 
one showing evidence that apoE can act as a transcription 
factor and influence a wide variety of signaling pathways 
(205). To circumvent the limitation of existing animal 
models, new experimental paradigms, particularly those 
derived from humans (such as iPSCs and brain organoids) 
need to be developed and characterized. An alternative ap-
proach is to engineer human A and/or Tau into species 
with more human-like physiology than rodents. These new 
experimental platforms will undoubtedly complement the 
current animal models and fuel a new wave of discovery 
that is necessary to fully understand AD pathology and its 
relationship with apoE, and to design new therapies.
In the next 25 years, the advancement of technology and 
the solid foundation built by many scientists in the last 25 
years should aid researchers with new tools and freedom to 
push the field toward a meaningful understanding of APOE 
and AD pathogenesis. From that insight, new and (hope-
fully) effective therapies can be designed that can alter the 
course of the disease.
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